Document Type : Original Article


1 Research Center for cancer epidemiology and screening. Aja University of Medical Sciences, Tehran, Iran.

2 Faculty of Biology, Women's university of semnan (Farzanegan), Semnan, Iran


TERT It has been shown that TERT is overexpressed in 90% of human cancers, and genetic alterations in the proximal promoter of TERT are significantly associated with a variety of different cancer types. In recent years, a new mechanism of TERT regulation through the non-coding driver mutations (C228T and C250T) in the TERT promoter has been reported in several cancer types. In the present study, we investigated the relationship between the Single Nucleotide Polymorphism (SNP) rs2853669 and cervical cancer.
The study included 80 individuals, including 50 patients with cervical cancer and 30 healthy controls. The samples from the participants underwent sequencing and genotyping using the Polymerase Chain Reaction - Restriction Fragment Length Polymorphism (PCR-RFLP) method.
It was found that 16%, 24%, and 60% of the cervical cancer samples had the genotypes of AA, AG, and GG, respectively. In the control group, the frequencies were 13.33%, 50%, and 36.66% of the samples for the genotypes of AA, AG, and GG, respectively. 
According to our findings, there was a significant association between the recessive model GG vs. AA+AG and cervical cancer susceptibility.


1. Low KC and Tergaonkar V: Telomerase: Central regulator of
all of the hallmarks of cancer. Trends Biochem Sci 38: 426-434,
2. Maciejowski J and de Lange T: Telomeres in cancer: Tumour
suppression and genome instability. Nat Rev Mol Cell Biol 18:
175-186, 2017.
3. Pestana A, Vinagre J, Sobrinho-Simões M and Soares P: TERT
biology and function in cancer: Besyond immortalisation. J Mol
Endocrinol 58: R129-R146, 2017.
4. Barthel FP, Wei W, Tang M, Martinez-Ledesma E, Hu X, A m
in SB, A kdem i r KC, Seth S, Song X, Wang Q, et al: Systematic
analysis of telomere length and somatic alterations in 31 cancer
types. Nat Genet 49: 349-357, 2017.
5. Sreedevi A, Javed R and Dinesh A: Epidemiology of cervical
cancer with special focus on India. Int J Womens Health 7:
405-414, 2015.
6. Schiffman M, Wentzensen N, Wacholder S, Kinney W, Gage
JC and Castle PE: Human papillomavirus testing in the prevention
of cervical cancer. J Natl Cancer Inst 103: 368-383, 2011.
7. Cancer Genome Atlas Research Network; Albert Einstein
College of Medicine; Analytical Biological Services; Barretos
Cancer Hospital; Baylor College of Medicine; Beckman Research
Institute of City of Hope; Buck Institute for Research on Aging;
Canada’s Michael Smith Genome Sciences Centre; Harvard
Medical School; Helen F. Graham Cancer Center & Research
Institute at Christiana Care Health Services, et al: Integrated
genomic and molecular characterization of cervical cancer. Nature
543: 378-384, 2017.
8. Khurana E, Fu Y, Chakravarty D, Demichelis F, Rubin MA and
Gerstein M: Role of non-coding sequence variants in cancer. Nat
Rev Genet 17: 93-108, 2016.
9. Horn S, Figl A, Rachakonda PS, Fischer C, Sucker A, Gast A,
Kadel S, Moll I, Nagore E, Hemminki K, et al: TERT promoter
mutations in familial and sporadic melanoma. Science 339:
959-961, 2013.
10. Liu X, Bishop J, Shan Y, Pai S, Liu D, Murugan AK, Sun
H, El-Naggar AK and Xing M: Highly prevalent TERT promoter
mutations in aggressive thyroid cancers. Endocr Relat Cancer 20:
603-610, 2013.
11. Killela PJ, Reitman ZJ, Jiao Y, Bettegowda C, Agrawal N, Diaz
LA Jr, Friedman AH, Friedman H, Gallia GL, Giovanella BC, et
al: TERT promoter mutations occur frequently in gliomas and a
subset of tumors derived from cells with low rates of self-renewal.
Proc Natl Acad Sci USA 110: 6021-6026, 2013.
12. Vinothkumar V, Arunkumar G, Revathidevi S, Arun K,
Manikandan M, Rao AK, Rajkumar KS, Ajay C, Rajaraman R,
Ramani R, et al: TERT promoter hot spot mutations are frequent
in Indian cervical and oral squamous cell carcinomas. Tumour
Biol 37: 7907-7913, 2016.
13. Park CK, Lee SH, Kim JY, Kim JE, Kim TM, Lee ST, Choi SH,
Park SH and Kim IH: Expression level of hTERT is regulated by
somatic mutation and common single nucleotide polymorphism at
promoter region in glioblastoma. Oncotarget 5: 3399-3407, 2014.
14. Spiegl-Kreinecker S, Lotsch D, Ghanim B, Pirker C, Mohr
T, Laaber M, Weis S, Olschowski A, Webersinke G, Pichler J
and Berger W: Prognostic quality of activating TERT promoter
mutations in glioblastoma: Interaction with the rs2853669
polymorphism and patient age at diagnosis. Neuro Oncol 17:
1231-1240, 2015.
15. Mosrati MA, Malmström A, Lysiak M, Krysztofiak A,
Hallbeck M, Milos P, Hallbeck AL, Bratthäll C, Strandéus
M, Stenmark-Askmalm M and Söderkvist P: TERT promoter
mutations and polymorphisms as prognostic factors in primary
glioblastoma. Oncotarget 6: 16663-16673, 2015.
16. Ko E, Seo HW, Jung ES, Kim BH and Jung G: The TERT
promoter SNP rs2853669 decreases E2F1 transcription factor
binding and increases mortality and recurrence risks in liver
cancer. Oncotarget 7: 684-699, 2016.